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AnalysisRedefining Clinical Trials: The
Age of Personalized MedicineThe triumph of personalized cancer therapeutics in recent years
is prompting some oncologists to rethink clinical trial design;
other researchers have different priorities for trial reform.As Hiroyuki Mano entered the oncology
ward at Seoul National University
Hospital, he was amazed to see his
patient walking around, asking people to
recommend the best local restaurant.
Just days before, the patient had been
hooked up to oxygen monitors. Cancer
had spread rapidly through his lung,
making it difficult to breathe and swallow.
He had been air-lifted from Japan to
Korea to get access to a clinical trial that
was testing a new drug, crizotinib.
The crizotinib trial was unusual be-
cause it did not contain a control arm for
placebo treatment. In 2008, Mano and
his colleagues at Jichi Medical University
identified a fusion protein of anaplastic
lymphoma kinase (ALK) with another
protein EML4, resulting from a chromo-
somal rearrangement seen in about 4%
of lung cancer patients. The ALK-EML4
fusion is a powerful driver of cancer but
is potently inhibited by crizotinib.Figure 1. Attrition Rate of Late-Stage Drug Dev
Data for phase II from 2008-2010 and Phase III from 2In this trial, doctors only enrolled
patients testing positive for the ALK bio-
marker. Crizotinib treatment resulted in
dramatic shrinkage of the tumors, visibly
and almost immediately, in some cases
within 48 hr. There could be no doubt
that the drug was working. Even though
only 82 patients were enrolled, the results
were clearly statistically significant.
Dr Mano’s patient was on his feet in days.
Trials on Trial
Beyond its immediate life-saving effects,
crizotinib and other recently approved
targeted therapeutics have changed
the landscape of oncology: clinicians are
rethinking the traditional model of
randomized controlled trials (RCTs) for
the era of personalized medicine.
RCTs are structured in four phases: The
first is a dose-response phase to find out
how much of a drug can be safely toler-
ated by patients. The second step is anelopment
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Cell 148escalation phase, where more patients
are enrolled, and the efficacy of the drug
is gauged. Many drugs that seem
extremely promising in the lab fail by
phase II. If they do succeed, the drugs
enter phase III, where higher numbers of
patients are enrolled, and the drug is
compared with the standard regimen.
The final phase is a post-marketing phase
that continues after a drug has been
licensed in order to study long-term
effects.
Usually, clinical trials enroll a large
number of patients to show that a
drug’s effects are statistically signif-
icant. Patients are randomly assigned to
a placebo or a drug arm, and neither the
doctor nor the patient knows which group
they are in. Such trials are described as
being randomized and double-blind.
However, it has become apparent
that most drugs that seem extremely
promising in the lab fail in the clinic.
Because of this, many have suggested
that trials ought to be restructured to get
a quicker ‘‘yes or no’’ answer before
millions of dollars and often a decade of
effort are sunk in getting an unsuccessful
drug through the early phases. Crizotinib,
especially, has given weight to this
argument: it took just 2 years to get
FDA approval—among the fastest in
known history. The success is indicative
of the power of personalized medicine at
its best.. Drug Discov. 10, 87.
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In addition, ethical concerns about
trial structure have surfaced, including
whether it is morally right to give a
placebo, or standard-of-care drug. Some
oncologists believe that this question of
ethics is especially valid in personalized
medicine, where the postulate is that all
patients with the relevant genetic lesion,
or biomarker, will respond to the drug.
In other diseases, however, it has been
more difficult for researchers to identify
genetic markers that predict a patient’s
response to a drug. How to improve trial
design in these cases is less clear.
The Exception or the Rule?
One of the few successes in pharmacoge-
netics has been with hepatitis C, where
David Goldstein, director of the Center
for Human Genome Variation at Duke
University, and his colleagues identified
an allele that predicts whether or not a
patient with hepatitis C will respond to
standard-of-care treatment.
‘‘I think it is entirely possible that in a
number of therapeutic areas, we will be
able to subdivide patients into genetic
subgroups that influence their responses
to treatments, but we just don’t have
manyexamples rightnow,’’ saysGoldstein.
Genome-wide association studies
(GWAS) have been heralded as a powerful
tool to identify genetic variance under-
lying human disease, but success has so
far been mixed. The vast numbers of
rare and ‘‘private’’ mutations that could
be responsible for individual responses
to treatment have confounded many
efforts to identify useful new biomarkers.
‘‘GWAS have most certainly not given
us a way to meaningfully partition patients
in the context of clinical trials,’’ says Gold-
stein.
So although promising results in hepa-
titis C and cancer could well indicate that
patient response in other diseases is simi-1080 Cell 148, March 16, 2012 ª2012 Elsevielarly governed by genetics, researchers
just do not have the data yet to prove or
disprove this theory. Biomarkers for most
diseases remain elusive.
The Hunt for Better Biomarkers
‘‘Many biomarkers people want to look at
are not binary; they are not a yes/no when
you run the test,’’ says Stuart Lutzker, vice
president of biooncology exploratory clin-
ical development at Genentech.
Robert Califf, vice chancellor for clinical
research at the Duke Translational Medi-
cine Institute, agrees: ‘‘The vast majority
of biomarkers are not accurate forwhether
or not treatment will work. That iswhy they
are biomarkers and not surrogates.’’
And even if a clear biomarker is present,
clinicians cannot usually waive a control
arm as in the crizotinib trial. Crizotinib
caused dramatic tumor shrinkage, leaving
no doubt of its potency, but most drugs
simply pause cancer growth. The only
way to judge a drug’s effect in such cases
is by comparing against patients who
have been given a placebo or standard-
of-care treatment.
Califf andcolleaguesarepart of theClin-
ical Trials Transformation Initiative, which
has been tasked by the FDA to reformclin-
ical trials. The rethink is not driven by the
hope of personalized medicine, says Cal-
iff. Rather, he says, they are trying to
streamline trials in order to reduce the
immense costs and high rates of failure.
Nonetheless, at least in the field of
oncology, clinicians believe that the
reform ought to go further, and patients
should be selected for trials with their
genetic makeup known from the very
start. This call for prescreening contrasts
with how trials are typically conducted.
Investigators usually enroll a large number
of patients, and once the trial has begun,
they may do a retrospective genetic anal-
ysis on some of them.r Inc.Personalized Drug Discovery
If the hypothesis is extended backward
into the drug discovery phase where
researchers administer drugs to tumor-
derived human cell lines, it suggests that
only a small fraction of the cell lines would
respond to any given drug. Many drugs
could be getting ruled out unnecessarily
as inactive before they even reach the
clinic.
Daniel Haber at the Massachusetts
General Hospital and his colleagues
suggest that an ideal human tumor cell
line profiling panel should consist of
between 2,000 and 6,000 cell lines.
However, there are only between 1,500
and 2,000 tumor-derived cell lines avail-
able in total today.
It is also important to detail the mo-
lecular pathways through which a drug
halts a tumor in order to identify new
targets once the cancer becomes resis-
tant to the drug in patients. Crizotinib,
for example, extends life by 6 months
to a year, but eventually the cancer
resurges. Haber suggests that this level
of detailed ongoing analysis should be
the standard for well-designed clinical
trials and calls for basic researchers to
be directly involved in trials from start to
finish.
Ira Mellman, vice president of oncology
at Genentech, would also like to see
greater collaboration. His view is that the
best model for human cancer is human
cancer. He declares that there is a moral
imperative to get as much information as
possible from patients, as early as enroll-
ment for phase I.
‘‘Every patient is making a sacrifice in
order to participate in these trials, espe-
cially when a drug is entirely experi-
mental and we have no evidence the
drug is going to work,’’ says Mellman.
‘‘We have to recognize that as a sacred
trust.’’Gayathri Vaidyanathan
London, UK
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